IPI finds improved tablet formulation

The Institute of Pharmaceutical Innovation (IPI) has been working with Galpharm International to help improve the robustness of one of its tabletted products.

Galpharm International, based in Barnsley, is a leading private label medicine supplier in the UK, delivering innovative products to the healthcare market. It was keen to work with the IPI after learning about the formulation and manufacturing process optimisation expertise available at the Institute.

Scientists at the IPI carried out compression studies on the samples provided, using their small-scale formulation laboratory to assess the effect of scale and compression force on differing formulations.

Initial analyses showed informative results in the behaviour of the alternative formulations and further data interrogation was carried out to understand more about the manufacturing conditions and optimal ingredients required to produce robust tablets.

The benefit of this project will enable Galpharm to produce a superior product, which will ultimately benefit the consumer. The improved formulation will also enable the company to run its manufacturing equipment more quickly, with fewer tablet breakages, and Galpharm is now predicting a significant upturn in both productivity and profitability.